A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of rAAV1-PG9DP when administered intramuscularly at different dose levels in healthy male adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine

NCT00482027

HIV Infection

COMPLETED PHASE1

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

NCT00107549

HIV Infections

COMPLETED PHASE1

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

NCT06557785

HIV Infections

ACTIVE_NOT_RECRUITING PHASE1

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001037

HIV Infections

COMPLETED PHASE1

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

NCT00001386

Acquired Immunodeficiency Syndrome HIV Infection

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a phase 1, randomized, blinded, dose-escalation study to evaluate the safety and tolerability of rAAV1-PG9DP when administered intramuscularly at 4x10\^12 vg, 4x10\^13 vg, 8x10\^13 vg and 1.2x10\^14 vg in healthy male adults.

Volunteers will be screened up to 42 days before injection and will be followed for 12 months after the single administration. It is anticipated that it will take approximately 13 months to enroll the study.

Volunteers will be randomly assigned investigational product (IP) or placebo within each of the dose groups described in the study design table above depending on which group is enrolling. Study staff and volunteers will be blinded only with respect to the allocation of placebo or IP. Blinding will not apply to the assignment of dosage levels.

Volunteers will be offered enrollment into a follow-up study at the research center when they have finished participating in the trial

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

rAAV1-PG9DP or placebo (v:p = 3:1)

Group Type EXPERIMENTAL

rAAV1-PG9DP

Intervention Type BIOLOGICAL

4x10\^12 vg administered intramuscularly

Group B

rAAV1-PG9DP or placebo (v:p = 3:1)

Group Type EXPERIMENTAL

rAAV1-PG9DP

Intervention Type BIOLOGICAL

4x10\^13 vg administered intramuscularly

Group C/C1

rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)

Group Type EXPERIMENTAL

rAAV1-PG9DP

Intervention Type BIOLOGICAL

8x10\^13 vg administered intramuscularly

Group D/D1

rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)

Group Type EXPERIMENTAL

rAAV1-PG9DP

Intervention Type BIOLOGICAL

1.2x10\^14 vg administered intramuscularly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rAAV1-PG9DP

4x10\^12 vg administered intramuscularly

Intervention Type BIOLOGICAL

rAAV1-PG9DP

4x10\^13 vg administered intramuscularly

Intervention Type BIOLOGICAL

rAAV1-PG9DP

8x10\^13 vg administered intramuscularly

Intervention Type BIOLOGICAL

rAAV1-PG9DP

1.2x10\^14 vg administered intramuscularly

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male.
2. 18 to 45 years of age.
3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
4. In the opinion of the Principal Investigator or designee and based on Assessment of Informed Consent Understanding results, has understood the information provided and has provided informed consent.
5. Willing to undergo HIV testing, risk reduction counseling and receive HIV test results.
6. All sexually active males must be willing to use male condoms with all sexual partners (female or male) from the day of first injection until 3 months after the injection.
7. Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV-positive due to vaccine-induced antibodies, until the anti-HIV antibody titers become undetectable.

Exclusion Criteria

1. Confirmed HIV-1 or HIV-2 infection.
2. Any clinically relevant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the investigator within the previous 6 months.
3. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator makes the volunteer unsuitable for participation in the study.
4. Any of the following specific risk behaviour for HIV infection within 6 months prior to injection:

* Unprotected sexual intercourse with a known HIV infected person or a partner known to be at high risk for HIV infection or a casual partner (i.e., no continuing established relationship)
* Unprotected anal intercourse with another man (either insertive or receptive)
* Three or more sexual partners
* Engaged in sex work
* Frequent excessive daily alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of illicit drugs
* History of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, HSV-2, chlamydia, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B
5. Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions).
6. Clinically significant laboratory abnormalities.
7. Anti-AAV1 antibody level above the cut-off.
8. Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after injection with IP; or receipt of other vaccine within the previous 14 days or planned receipt within 14 days after injection with IP (exception is live attenuated influenza vaccine within 14 days).
9. Receipt of blood transfusion or blood-derived products within the previous 3 months.
10. Participation in another clinical trial of an IMP currently, within the previous 3 months or expected participation during this study.
11. Prior receipt of another AAV vector, investigational HIV vaccine candidate, monoclonal antibody or polyclonal immunoglobulin (note: receipt of placebo in a previous HIV vaccine or monoclonal antibody trial will not exclude a volunteer from participation).
12. History of severe local or systemic reactogenicity to vaccines or infusions (e.g., anaphylaxis, respiratory difficulties, angioedema)
13. Psychiatric condition that compromises safety of the volunteer and precludes compliance with the protocol.
14. In the opinion of the Principal Investigator, it is not in the best interest of the volunteer to participate in the trial.
15. Seizure disorder: a participant who has had a seizure in the last 3 years.
16. ECG with clinically significant findings or features.
17. History of, or known active cardiovascular disease.
18. Have 3 or more of the following risk factors:

* Hypertension diagnosed by a doctor
* Hypercholesterolemia diagnosed by a doctor
* Diabetes mellitus
* Hyperglycemia diagnosed by a doctor
* First degree relative (i.e., mother, father, brother, sister) who had a heart condition before the age of 50
* Currently smoke cigarettes

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes